RxDoctor Payments Data

Dylan Kilmer

Psychiatric/Mental Health · Greenfield Township, PANPI 1679198220

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $36,850 of the $43,958 with a category attached, or 83.8%. AbbVie accounts for 92.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $25,174 and has fallen 56.9% since, to $10,847 in 2025. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$43,958in general payments, 2019–2025

Across 306 payments — averaging $143.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$41K
  • Teva Pharmaceuticals USA, Inc.$572
  • Otsuka America Pharmaceutical, Inc.$540
  • Johnson & Johnson$516
  • Neurocrine Biosciences, Inc.$497
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$304
  • plus $823 from 15 others

What the payments were for

  • Speaking & faculty fees$36,85084%
  • Travel & lodging$2,2855%
  • Food & beverage$4,82311%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,958 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine14$226,073
IngrezzaValbenazine Tosylate19$195,119
AustedoDeutetrabenazine15$174,308
Invega SustennaPaliperidone Palmitate25$86,757
Abilify MaintenaAripiprazole29$81,109
VraylarCariprazine Hcl45$64,802
TrintellixVortioxetine Hydrobromide21$9,828
Lurasidone Hcl18$7,966
Clozapine13$827
Aripiprazole23$749
Lamotrigine83$698
Bupropion XlBupropion Hcl20$522
Paroxetine Hcl28$454
Alprazolam74$450
Venlafaxine Hcl ErVenlafaxine Hcl27$416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$572$400,38129 claims
Neurocrine Biosciences, Inc.Ingrezza$497$195,11919 claims
Johnson & JohnsonInvega Sustenna$516$86,75725 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$540$81,10929 claims
AbbVieVraylar$40,706$64,80245 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$21$9,82821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Greenfield Township

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →